蛋白酶激活的CendR,向纳辛-C:减轻非标组织积累的作用
Allan Tobi1, Maarja Haugas1, Kristina Rabi1
1Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, 50411, Tartu, Estonia.
Drug delivery and translational research
|July 16, 2024
概括
研究人员开发了针对癌症的新型,仅在遇到尿酶类型等离子体激活剂 (uPA) 后才能激活. 这种精确的方法减少了表达神经皮林-1 (NRP-1) 的健康组织中的非目标积累,改善了癌症治疗的交付.
科学领域:
- 生物技术和制药科学 生物技术和制药科学
- 分子和细胞生物学分子和细胞生物学
- 在瘤学瘤学.
背景情况:
- 针对瘤的抗癌化合物和纳米粒子 (NP) 需要精确的连接剂.
- C-end规则 (CendR) 具有瘤透能力,但可以结合表达神经皮林-1 (NRP-1) 的非标组织.
- 一个CendR的PL3,通过其C端RLVR元素随性结合NRP-1.
研究的目的:
- 设计PL3衍生物,通过尿素酶类型等离子体激活剂 (uPA) 进行蛋白质分解激活后选择性地结合NRP-1.
- 为了保持与素-C C-域 (TNC-C) 的结合亲和力,同时实现依赖uPA的NRP-1参与.
- 开发一种针对蛋白质分解活性瘤透的查技术.
主要方法:
- 基于PL3的uPA处理的菌体库的合理设计和选.
- 只有在uPA裂变后才能结合复合NRP-1的衍生物的鉴定.
- 在实验室测定 (裂变,结合,内化) 和在glioblastoma小鼠模型中的体内生物分布研究.
主要成果:
- 确定了两个新型,PL3uCendR和SKLG,表现出对NRP-1的uPA-依赖结合.
- 这些保持与TNC-C的结合,同时表现出对健康的NRP-1表达组织的减少的非目标结合.
- 在体内研究证实了开发的的向传递和有效性.
结论:
- 已经成功开发了针对TNC-C和NRP-1的新型uPA依赖的CendR.
- 这项研究建立了一种用于选蛋白质分解活性瘤透的技术.
- 开发的提供了一个有前途的策略,用于精确瘤向和减少癌症治疗中的全身毒性.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Translocation of Proteins into the Mitochondria
3.1K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.1K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Caspases
12.4K
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
12.4K
Mitochondrial Precursor Proteins
2.6K
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70 chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial...
Most of the mitochondrial...
2.6K


